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Alzheimer’s disease is characterized by the accumulation of neurotoxic amyloidogenic peptide A, degeneration of the cholinergic
innervation to the hippocampus (the septohippocampal pathway), and progressive impairment of cognitive function, particularlymem-
ory. A is a ligand for the p75 neurotrophin receptor (p75NTR), which is best known for mediating neuronal death and has been
consistently linked to the pathology of Alzheimer’s disease. Here we examined whether p75NTR is required for A-mediated effects.
Treatment of wild-type but not p75NTR-deficient embryonic mouse hippocampal neurons with human A1–42 peptide induced signifi-
cant cell death. Furthermore, injection ofA1–42 into the hippocampus of adultmice resulted in significant degeneration ofwild-type but
not p75NTR-deficient cholinergic basal forebrain neurons, indicating that the latter are resistant to A-induced toxicity. We also found
that neuronal death correlated with A1–42 peptide-stimulated accumulation of the death-inducing p75
NTR C-terminal fragment gener-
ated by extracellular metalloprotease cleavage of full-length p75NTR. Although neuronal death was prevented in the presence of the
metalloprotease inhibitor TAPI-2 (tumor necrosis factor- protease inhibitor-2), A1–42-induced accumulation of the C-terminal frag-
ment resulted from inhibition of-secretase activity. These results provide anovelmechanism to explain the early and characteristic loss
of cholinergic neurons in the septohippocampal pathway that occurs in Alzheimer’s disease.
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Introduction
Alzheimer’s disease is a neurodegenerative disorder character-
ized by senile plaque pathology, neurofibrillary tangles, and neu-
ronal death, with resultant impairment of memory and cognitive
function. Amyloid  protein (A), the major component of se-
nile plaques, is a 39–43 aa peptide produced by cleavage of the
amyloid protein precursor. According to the “amyloid hypothe-
sis,” accumulation of soluble A in the brain is the primary cause
of the pathogenesis of Alzheimer’s disease (Hardy and Selkoe,
2002), but with A oligomers rather than amyloid deposits being
the cause of the neurotoxicity associated with this condition
(Dahlgren et al., 2002; Klein et al., 2004; Gandy, 2005).
Loss of basal forebrain cholinergic neurons that innervate the
hippocampus and neocortex is an early and key feature of Alzhei-
mer’s disease (Yan and Feng, 2004; Wu et al., 2005). These cho-
linergic neurons express high levels of the p75 neurotrophin re-
ceptor (p75NTR), which mediates cell death in a wide range of
neuronal subtypes (Dechant and Barde, 2002). p75NTR expres-
sion has been consistently linked to changes occurring in Alzhei-
mer’s disease (Schliebs, 2005), including the death of basal fore-
brain neurons (Yeo et al., 1997; Volosin et al., 2006). Like the
amyloid protein precursor (APP), the extracellular domain of
p75NTR is cleaved by a metalloprotease, generating a
transmembrane-linked C-terminal fragment. This is then
cleaved by -secretase, liberating a soluble intracellular domain
(Jung et al., 2003). Ligand binding can initiate this process, and
both fragments of p75NTR have been shown to mediate death
signaling (Kenchappa et al., 2006; Podlesniy et al., 2006; Coulson
et al., 2008; Underwood et al., 2008).
The classic p75NTR ligands are the neurotrophins nerve
growth factor, brain-derived neurotrophic factor, and
neurotrophin-3. These are secreted as immature forms (proneu-
rotrophins), which are sometimes cleaved to produce themature
forms (Fahnestock et al., 2001). It has previously been proposed
that increased levels of proneurotrophins, such as occur in Alz-
heimer’s disease, may underlie cholinergic neuronal degenera-
tion (Fahnestock et al., 2001; Volosin et al., 2006). However, it is
also possible that A could be directly responsible for activating
p75NTR-mediated cell death inAlzheimer’s disease, given that it is
a ligand for the receptor (Yaar et al., 1997) and can stimulate
p75NTR-mediated death signaling cascades in cell lines (Costan-
tini et al., 2005; Coulson, 2006). In this study, we provide evi-
dence of a direct link between p75NTR signaling and A-induced
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toxicity in hippocampal neurons in vitro and in cholinergic basal
forebrain neurons in vivo.
Materials andMethods
A preparation.Human A1–42 peptide and control human A1–16 pep-
tide were purchased fromDr. J Elliot (Yale University, NewHaven, CT).
Unless otherwise stated, peptides were dissolved in sterile water at a
concentration of 200 M and stored at 4°C (Yaar et al., 1997). Peptide
solutions were incubated at 37°C for 1 h before experimental use and
were found to occur in a predominantly oligomeric form (supplemental
Fig. 1A, available at www.jneurosci.org as supplementalmaterial), which
was more toxic to hippocampal neurons than the fibrillar form (supple-
mental Fig. 1B,C, available at www.jneurosci.org as supplemental
material).
Hippocampal cultures. All animal experiments were approved by the
University of Queensland Animal Ethics Committee. When examining
the effects of genotype, experiments were performed in parallel. Hip-
pocampi were dissected from embryonic day 16 (E16) wild-type and
p75NTR-knock-out (Lee et al., 1992) C57BL/6 mice. They were then
dissociated in 0.05% trypsin (Invitrogen, Melbourne, Australia), plated
on 35 mm dishes coated with poly-L-lysine (0.1 mg/ml; Sigma-Aldrich,
Sydney, Australia), and cultured for 24 h in a 1:1 mixture of minimal
essential medium (Invitrogen) and Ham’s F-12 medium (Invitrogen)
supplemented with NeuroCult (StemCell Technologies, Vancouver,
British Columbia, Canada). Approximately 95% of cells within the cul-
tures were p75NTR-positive neurons (supplemental Fig. 2A,B, available
at www.jneurosci.org as supplemental material). Live cells within a de-
fined grid were then counted (t  0) under phase microscopy (n  4
wells per condition per experiment). A peptides or inhibitors were
dissolved in fresh culture medium and applied after the t 0 cell count.
The final concentrations were 5 or 20MA peptides, a 1:100 dilution of
anti-extracellular p75NTR antibody (Ab1554; Millipore Bioscience Re-
search Reagents,Melbourne, Australia), 200 nM compound E-secretase
inhibitor (Calbiochem, Melbourne, Australia), and 20 M tumor necro-
sis factor- protease inhibitor-2 (TAPI-2; Peptides International, Louis-
ville, KY). In some experiments using the metalloprotease inhibitor
TAPI-2, a second 20 M dose of TAPI-2 was added into the culture
medium at t 6 h. Twenty-four hours after A treatment, the viability of
the same neurons was again assessed, and the percentage survival was
determined.
p75NTR cleavage in hippocampal neurons.To determine the effect of A
treatment on the proteolysis of p75NTR, hippocampal neurons plated in
six-well plates for 24 h were pretreated with 5 M -clasto-lactacystin
(Calbiochem) proteasome inhibitor for 90 min, after which they were
treated for 3 h with a mixture of 20 M A1–42, 200 nM compound E,
and/or 200 nM phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich).
Cell lysates were separated using 4–20% Tris-glycine gradient gels (In-
vitrogen) and Western blotted using rabbit anti-human p75NTR intra-
cellular domain (1:2000; Promega, Sydney, Australia). Immunoreactive
bands were quantified using ImageJ software. The amount of C-terminal
fragment was determined as a ratio to full-length p75NTR within each
lane.
DNA constructs. Full-length p75NTR rat cDNA was as previously de-
scribed (Coulson et al., 2000). A p75NTR C-terminal fragment mimic
that is constitutively cleaved (E14) was made as described by Jung et al.
(2003). The C99 APP plasmid contained Gal4 DNA binding and VP16
transactivation domains fused to the carboxyl end (C99-Gal4) (Sernee et
al., 2003). A E14 construct was similarly modified (E14-Gal4) using
standard methods. The luciferase reporter gene construct (pUAS) and
the constitutively active plasmid (pCMV-Gal) were as previously de-
scribed (Karlstrom et al., 2002).
p75NTR cleavage in HEK293 cells. The effect of A treatment on the
proteolysis of p75NTR was determined using human embryonic kidney
293 (HEK293) cells grown in RPMI (Roswell Park Memorial Institute)
medium and 10% fetal bovine serum. Cells were plated at 7.5  104 in
24-well plates and transiently transfected with 1 g of plasmid DNA
using Fugene6 (Roche, Basel, Switzerland) per well. A1–42 (16 M) was
added to the cells either 48 (overnight treatment) or 52 (3 h treatment)
hours after transfection. Before cell harvest, cells were treated with
-clasto-lactacystin, compound E, and PMA as described above. Cell
lysates were Western blotted and the results were analyzed as described
above.
Luciferase cleavage assay. For luciferase experiments, HEK293 cells
were plated and transfected with the pUAS plasmid together with the
E14-Gal4, C99-Gal4, or pCMV-Gal plasmid. The cells were then incu-
bated overnight and/or for 3 h in A or compound E, before being
harvested in reporter lysis buffer. Lysis supernatant (20 l) was assessed
using the Luciferase Activity System according to the manufacturer’s
instructions (Promega). In each experiment, three to six replica lysates
were analyzed. The total protein in each lysate was also quantified using
a BCA assay kit (Pierce, Rockford, IL).
A injections. Eight-week-old wild-type and p75NTR knock-out
C57BL/6 mice were anesthetized with 8 mg/kg xylazine and 80 mg/kg
ketamine by intraperitoneal injection and mounted in a stereotaxic
frame. The skull was exposed and a burr hole made at stereotaxic coor-
dinates measured from bregma (anteroposterior, 2.0 mm; mediolat-
eral,1.3 mm; ventral,2.2 mm), through which 0.5l of saline or 100
g/ml A was injected into the CA1 region of the hippocampus at a rate
of 0.5 l/min. The needle was kept in this configuration for 2 min to
prevent reflux of the injected material along the injection track. In cases
in which mice were administered bilateral injections, they received
A1–16 ipsilaterally and saline contralaterally, or A1–42 ipsilaterally and
A1–16 contralaterally. Animals were perfused with 4% paraformalde-
hyde 14 d after injection.
Histology. To determine cell survival of cholinergic basal forebrain
neurons, the rostral half of each brain between1.4 and0.5 mm from
bregma (the medial septum and diagonal band of Broca) was cut by
vibratome into 15 60-m-thick serial coronal sections. Floating sections
were stained with a rabbit anti-choline acetyltransferase (ChAT) poly-
clonal antibody (1:500; Ab143;Millipore Bioscience Research Reagents),
and all ChAT-positive neurons in the area of interest were counted based
on the method of Greferath et al. (2000).
Statistical analysis. The data were analyzed by ANOVA using the New-
man–Keuls multiple-comparison test. All results are expressed as
mean SD.
Results
To investigate whether p75NTR is required for A-induced neu-
ronal death, we first established an in vitro model of toxicity in
E16 embryonic hippocampal neuron cultures, which have been
found to be independently sensitive to both A- (Ueda et al.,
1994) and p75NTR-mediated death (Troy et al., 2002). We found
that 24 h after plating in serum-free medium, neurons were sen-
sitive to an overnight incubation with oligomeric 5 or 20 M
A1–42 but not 20 M A1–16 or vehicle (Fig. 1A).
To test whether p75NTR was required for the observed neuro-
nal death, the effect of A1–42 on hippocampal neurons isolated
from p75NTR-deficient mice was determined. In contrast to the
results obtained with wild-type neurons, A1–42 failed to induce
the death of p75NTR-deficient neurons even at 20 M (Fig. 1A),
indicating that p75NTR is required for A-induced death in vitro.
An extracellular antibody to p75NTR also significantly inhibited
A1–42-induced hippocampal cell death (Fig. 1B).
Given that A is a known ligand for p75NTR, the effect of
A1–42 on p75
NTR proteolytic processing was next examined.
Hippocampal neurons were treated for 3 h with 20 M A1–42
before analysis by Western blot (Fig. 2A). This analysis revealed
that neurons exposed to A1–42 contained significantly more
p75NTR C-terminal fragment than control neurons (Fig. 2B), the
amount being equivalent to that found when intracellular cleav-
agewas blockedwith compoundE, a-secretase inhibitor, for the
same period of time (Fig. 2A,B). An intracellular domain frag-
ment of p75NTR was not apparent. To determine whether cleav-
age was required for death signaling, extracellular cleavage was
blocked with the metalloprotease inhibitor TAPI-2 (Jung et al.,
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2003). This completely inhibited A1–42- but not staurosporine-
induced neuronal death in a dose-dependent manner (Fig.
2C,D). In contrast, compound E treatment resulted in a slight
increase in A-induced death (Fig. 2E).
To further examine the effect of A on p75NTR cleavage,
p75NTR was expressed in HEK293 fibroblast cells. Overnight
treatment [but not 3 h treatment (supplemental Fig. 3A, available
at www.jneurosci.org as supplemental material)] with A1–42 re-
sulted in a significant increase in the amount of C-terminal frag-
ment (Fig. 3A,B). However, in contrast to phorbol ester (PMA)
treatment, there was less generation of the intracellular domain
fragment of p75NTR (Fig. 3C). Interestingly, when the two treat-
ments were combined, the resulting cleavage appeared cum-
ulative (Fig. 3A–C; supplemental Fig. 3A, available at www.
jneurosci.org as supplemental material), suggesting that their ac-
tions were independent, possibly acting on different subcellular
pools of p75NTR. Because increased amounts of C-terminal frag-
ment could result from either increased metalloprotease activity
or reduced -secretase activity, and coexpression of an APP
-secretase substrate (C99) together with p75NTR also signifi-
cantly promoted accumulation of the p75NTR C-terminal frag-
ment (supplemental Fig. 2A, available at www.jneurosci.org as
supplemental material) (Urra et al., 2007), we hypothesized that
A1–42 might be competing with p75
NTR for -secretase activity,
rather than, or as well as, acting as a p75NTR ligand to promote
extracellular cleavage.
Therefore, we next tested whether A could alter the rate of
intracellular cleavage of a p75NTR protein lacking the extracellu-
lar domain (E14) (Jung et al., 2003). Although not as efficient as
treatment with a -secretase inhibitor, cells treated overnight
with A had discernibly less intracellular domain fragment than
untreated cells (Fig. 3D). To quantify this, we used a E14 con-
struct and a similar APP construct (C99-Gal4) in which the Gal4
transactivation domains had been fused to their carboxyl ends
(Sernee et al., 2003). Only when released after -secretase cleav-
age of the C-terminal protein can the activator domain promote
transcription of a cotransfected luciferase reporter gene (pUAS),
the activity of which can be fluorometrically quantified in cell
lysates (Karlstrom et al., 2002). Using this method, we found that
overnight treatment ofE14-Gal4-expressing HEK293 cells with
A1–42 significantly inhibited the resultant luciferase activity,
whereas the control peptide A1–16 had no significant effect (Fig.
3E). Importantly, our results using the C99-Gal4 construct also
showed a significant effect after an overnight A treatment regi-
men, which was similar to the level of inhibition seen when the
-secretase inhibitor was applied overnight (Fig. 3F). Given that
the assay is based on a transcriptional readout, it was not surpris-
ing that no significant effects were seen after the 3 h treatments.
These results indicate that A1–42 can generically inhibit
-secretase activity, and suggest that the increased level of
p75NTR C-terminal fragment in cells treated with A is, at least
partially, caused by this effect.
Loss of basal forebrain cholinergic neurons through degener-
ation of the septohippocampal pathway is a major feature of
Figure 1. A1–42-induced toxicity of hippocampal neurons requires p75
NTR. A, The per-
centage survival of cells after treatment with A1–42 or control peptide A1–16. Wild-type
(WT) but not p75 NTR-deficient (KO) neuronswere sensitive toA1–42-induced toxicity. A1–16
had no effect on neuronal survival. B, Treatment of wild-type hippocampal neuronal cultures
with a p75 NTR-blocking antibody (Ab1554) significantly inhibited A1–42 toxicity. n 4 ex-
periments. *p 0.05; ***p 0.001.
Figure 2. A1–42 toxicity regulates and requires extracellular cleavage of p75
NTR. A, Anti-
p75 NTR Western blots of hippocampal neuronal cultures treated for 3 h with A1–42 and the
-secretase inhibitor compound E (CpdE). All conditions contain-clasto-lactacystin.B, These
treatments result in a significant increase in the amount of C-terminal fragment (CTF) as a ratio
of full-length (FL) p75 NTR as quantified by densitometry. C, D, A1–42 toxicity (C) but not
staurosporine (stauro) toxicity (D) is significantly inhibited after treatment with the metallo-
protease inhibitor TAPI-2. x2, Double TAPI-2 treatment. n 3 experiments. E, A1–42 toxicity
is promoted in the presence of CpdE. n 2 experiments. *p 0.05; ***p 0.001.
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Alzheimer’s disease. To determine whether
A1–42-induced toxicity in cholinergic
neurons innervating the hippocampus was
mediated by p75NTR, A1–42 or A1–16
peptide solution was injected into the hip-
pocampus of wild-type and p75NTR-
deficient mice. Fourteen days after the in-
jection, the septohippocampal pathway
was examined histologically. Regardless of
the injected solution or mouse genotype,
the needle track through the CA1 region
of the hippocampus was identified, reveal-
ing no obvious difference in the amount of
tissue damage in this area (supplemental
Fig. 4, available at www.jneurosci.org as
supplemental material). In contrast, the
number of ChAT-positive neurons in the
medial septum and diagonal band of Broca
after A1–42 exposure was affected by ge-
notype. First, the number of ChAT-
positive neurons in the diagonal band of
Broca of the ipsilateral hemisphere of wild-
type mice injected with saline (n 4, data
not shown) or A1–16 was not significantly
different from that found in uninjected
hemispheres (Fig. 4A). However, the num-
ber of ChAT-positive neurons in the same
region of mice injected with A1–42 was
significantly reduced compared with that
of uninjected, saline-injected, or A1–16-
injected animals (Fig. 4A,B). Most impor-
tantly, however, the number of ChAT-
positive neurons in p75NTR-deficient mice
after injection with A1–16 or A1–42 did
not differ significantly, and was similar to
that found in uninjected wild-type mice
(Fig. 4A,C). These results demonstrate
that p75NTR is also required for A1–42-
mediated neuronal toxicity in vivo.
Discussion
Here we provide evidence that p75NTR is
required for oligomeric A1–42-mediated
neuronal death in vitro and in vivo, further strengthening the case
that p75NTR plays a role in the etiology of Alzheimer’s disease.
We found that embryonic hippocampal neurons, which, un-
like their adult counterparts, express high levels of p75NTR, were
killed by bathing the cultures with oligomeric A1–42 peptides,
but were unaffected by A1–16 peptides. This finding is in agree-
ment with many other studies showing that the carboxyl amino
acids of the amyloid peptide are important for neuronal toxicity
(Klein et al., 2004; Costantini et al., 2005), and supports themore
recent idea that the soluble oligomeric protofibril form of A1–42
mediates amyloid neurotoxicity (Dahlgren et al., 2002; Gandy,
2005).Moreover, we demonstrated that A1–42-mediated neuro-
toxicity is abolished in the absence of p75NTR expression. This
confirms the involvement of p75NTR-mediated signaling path-
ways in neuronal death reported in previous studies using non-
primary cell cultures treated with amyloid peptides (Coulson,
2006).
We found that A-mediated death signaling resulted in, and
required, increased production of the p75NTR C-terminal frag-
ment. It has been demonstrated that A binds to the extracellular
domain of p75NTR (Yaar et al., 1997), and that p75NTR mediates
death signaling in hippocampal neurons after neurotrophin ap-
plication (Troy et al., 2002). We found that an antibody to the
p75NTR extracellular domain had a significant effect on A1–42-
induced death. It is therefore possible that the interaction of
A1–42 with p75
NTR promotes extracellular cleavage, such as oc-
curs in response to other p75NTR ligands (Kenchappa et al., 2006;
Podlesniy et al., 2006; Coulson et al., 2008). Although it is also a
possibility that the antibody was preventing the binding and ac-
tivation of p75NTR by endogenously produced neurotrophins
(Troy et al., 2002; Volosin et al., 2006), the fact that -secretase
inhibitor treatment failed to promote cell death in the absence of
A1–42 suggests that additional A1–42 effects may play a role in
the promotion of cell death.
Our experiments using HEK293 cells indicate that inhibition
of -secretase activity is a significant factor in promoting the
accumulation of the C-terminal fragment. Although the exact
mechanism by which this occurs is not known, our finding that
APP processing is also affected by A, together with the demon-
stration that increased expression of the APP C-terminal frag-
Figure 3. A1–42 inhibits -secretase cleavage of p75
NTR. A–C, Western blot (A) and quantification of the amount of the
C-terminal fragment (CTF; B) and intracellular domain fragments (ICD; C) of p75 NTR in lysates of HEK293 cells transfected with
full-length (FL) p75 NTR before overnight treatment with A1–42 and/or 3 h treatment with PMA and/or compound E (CpdE). All
cultures were treated with -clasto-lactacystin. D, Western blot of p75 NTR C-terminal fragment mimic 14 in lysates of
transfected HEK293 cells after overnight treatment with A1–42 or 3 h treatment with CpdE or PMA. E, F, Luciferase activity in
lysates of HEK293 cells coexpressing 14-Gal4 (E) or C99-Gal4 (F ) together with pUAS (black bars) after treatment with
A1–16, A1–42, or CpdE. Gray bars indicate positive-control (pCMV-Gal- andpUAS-transfected cells) andnegative-control (cells
transfectedwith pUAS alone) conditions. The total amount of total protein in lysates (white bars; inmicrograms permicroliter) is
also shown in E (n 6 samples from 2 experiments). *p 0.05; **p 0.01; ***p 0.001. n 4 experiments for all other
conditions.
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ment has a similar effect on p75NTR processing, suggests that
A1–42 could act as a competitive -secretase substrate. This
mode of action, in agreement with our finding that -secretase
inhibitor treatment promoted rather than inhibited A-induced
neuronal death, would precludeA-induced cell death beingme-
diated via the intracellular domain pathway described by others
(Kenchappa et al., 2006; Podlesniy et al., 2006).However, we have
previously shown that the C-terminal fragment of p75NTR is con-
stitutively active in signaling neuronal death, and have recently
defined a signaling cascade by which it results in caspase activity
(Coulson et al., 2000, 2008; Underwood et al., 2008).
In support of p75NTR playing a key role in A1–42-induced
neurodegeneration, we found that injection of A1–42 into the
hippocampus of wild-type mice, a model of Alzheimer’s disease,
resulted in the degeneration of ChAT-positive forebrain neurons
in vivo. Although our analysis did not specifically determine that
ChAT-positive cells had died after A1–42 exposure at axonal
terminals, it did demonstrate the loss of cellular neurotransmitter
production and hence loss of function of these neurons. It has
also been shown in aged animals that ChAT downregulation cor-
relates with loss of hippocampal function (Yeo et al., 1997) and
that this precedes the death of basal forebrain neurons (Greferath
et al., 2000).
This functional loss of cholinergic forebrain neurons in vivo
was also prevented by p75NTR deficiency, supporting the hypoth-
esis that p75NTR-mediated degeneration of basal forebrain neu-
rons is an early consequence of increased oligomeric A levels
and is tightly linked to the loss of septohippocampal function
observed in both animal models and hu-
man patients with Alzheimer’s disease
(Klein et al., 2004; Gimenez-Llort et al.,
2007). Although a significant difference in
the numbers of ChAT-positive basal fore-
brain neurons correlated directly with
A1–42 exposure, we found no obvious dif-
ference in the amount of damage in the
hippocampus after injections into the CA1
region, regardless of A peptide length or
genotype. In the adult hippocampus, un-
like the embryonic hippocampus and the
adult basal forebrain, p75NTR is downregu-
lated, although it can be upregulated in re-
sponse to injury (Dechant and Barde,
2002). This observation further highlights
the connection between the degeneration
of neurons that express high levels of
p75NTR and A1–42 peptide exposure. Al-
though our in vitro results demonstrate
that A1–42-induced, p75
NTR-mediated
neuronal death is likely to result from inhi-
bition of -secretase activity, other injury-
induced factors, such as modulation of
synaptic plasticity (Klein et al., 2004),
and/or neurotrophins released by reactive
astrocytes (Pehar et al., 2004), could also
contribute to, and indeed may be required
to, promote cell death in vivo via a p75NTR-
dependent mechanism.
In conclusion, we have shown that A1–
42-induced neuronal degeneration of em-
bryonic hippocampal neurons in vitro and
basal forebrain neurons in vivo requires
p75NTR. Furthermore, the activation of
neuronal loss strongly correlates with increased accumulation
of the constitutively active death-signaling C-terminal fragment
of p75NTR generated by inhibition of -secretase activity. Al-
though p75NTR has been causally linked to the progression of
Alzheimer’s disease for over a decade, the current results provide
a novel mechanism to explain the early and characteristic degen-
eration of the septohippocampal pathway that occurs in this
disease.
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